Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | STS | P08842 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18012785 | 0.93 | PPARG (0.36) | CA2PKMHSD17B3MAPT | |
| SCHEMBL18012776 | 0.90 | PKM (0.40) | PKMMAPTTHRBL3MBTL1NPSR1 | |
| SCHEMBL18012820 | 0.89 | CA2 (0.37) | CA2PKMHSD17B3MAPTPTGS2 | |
| SCHEMBL18012833 | 0.88 | MAPT (0.40) | PKMMAPTTHRBL3MBTL1PTGS2 | |
| SCHEMBL18012773 | 0.86 | CA2 (0.38) | CA2PKMHSD17B3MAPTPTGS2 | |
| SCHEMBL18012818 | 0.85 | PKM (0.37) | PKMMAPTTHRBL3MBTL1NPSR1 | |
| SCHEMBL18012834 | 0.84 | RAB9A (0.39) | CA2PKMTHRBL3MBTL1 | |
| SCHEMBL18012626 | 0.83 | THRA (0.39) | CA2PKMMAPTTHRB | |
| SCHEMBL21431241 | 0.83 | CA2 (0.32) | CA2PKM | |
| SCHEMBL18012725 | 0.82 | MAPT (0.42) | PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016126070-A1 | NOVEL OXIMESTER DERIVATIVE COMPOUND, AND PHOTOPOLYMERIZATION INITIATOR AND PHOTORESIST COMPOSITION CONTAINING SAME | 한국화학연구원 | 2016-08-11 | — | — | WO | disclosed |